An alternative CRISPR-Cas nuclease for biotech & pharma Specialty Chemicals has published…
Read moreof our journey
HOW DOES IT WORK?
You can directly support our growth story from the beginning and be a financial sponsor and value appreciation partner.
Akribion Genomics is currently executing Series A financing. We are looking for investors which believe in our mission that genome editing enables the biotech revolution.
WHY SHOULD YOU INVEST?
High value potential
Strong growth with highly attractive licensing opportunity
Attractive therapeutic area focus, novel solution
Big impact on patients and largest TA by sales
Customer-proven technology
Already licensed and used in Contract R&D
Strong and committed team
Seasoned mgmt. team and entrepreneurial R&D team
De-risked business model
Adjacent segments with early & existing revenues
Strong network
Customers and partners
GET IN TOUCH
If you are interested to learn more about Akribion Genomics as a company or to become part of the Akribion journey, feel free to reach out to us: investors@akribion-genomics.com
NEWS & PUBLICATIONS
Akribion Genomics receives the Hessian Founder Award for its innovative approach to…
Read moreBRAIN Biotech AG’s Akribion Genomics technology receives patent approval for its groundbreaking…
Read moreBRAIN Biotech AG Scientist receives VAAM Innovation Award for the discovery of…
Read moreAkribion Genomics successfully competes in Science4Life Venture Cup competition
Read moreBRAIN Biotech and TransCode Therapeutics join forces to develop a CRISPR-derived technology…
Read moreBRAIN Group’s Akribion Genomics business will prioritize the development of therapeutic applications…
Read more